A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Abstract Background Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS), combined with CD4 T cell activation, would suppor...

Description complète

Détails bibliographiques

Auteurs principaux:	Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese-Bullock, Nolan A. Wages, William W. Grosh, Nikole Varhegyi, Mark E. Smolkin, Kelly T. Smith, Nadejda V. Galeassi, Donna H. Deacon, Elizabeth M. Gaughan, Craig L. Slingluff
Format:	Artigo
Langue:	Inglês
Publié:	BMJ Publishing Group 2019-06-01
Collection:	Journal for ImmunoTherapy of Cancer
Sujets:	Melanoma Peptide vaccine Incomplete freund’s adjuvant Toll-like receptor Lipopolysaccharide polyICLC
Accès en ligne:	http://link.springer.com/article/10.1186/s40425-019-0625-x
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!